由携带CD19作为CAR目标的泡病毒引起的瘤溶解,通过基因组修饰逃避CART检测
Jason M Tonne1, Karol Budzik1, Talia Fernandez Carrasco1,2
1Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Molecular therapy. Oncology
|September 2, 2024
概括
显示CD19抗原的瘤泡状病毒 (oFV) 与仿真抗原受体 (CAR) T细胞对固体瘤的有效性有限. 高剂量的oFV单独是最有效的,这表明CAR T细胞可能会阻碍oFV治疗.
科学领域:
- 在瘤学瘤学.
- 病毒学 病毒学
- 免疫治疗是一种免疫疗法.
背景情况:
- 化学抗原受体 (CAR) T细胞对固体瘤的成功有限.
- 瘤病毒 (oVs) 提供了一种增强抗瘤免疫力的潜在策略.
研究的目的:
- 为了研究一种致癌泡状病毒 (oFV) 的组合,该病毒被设计为显示CAR T细胞向抗原 (CD19) 与抗CD19CAR T细胞的结合,用于固体瘤治疗.
- 评估病毒传播和抗原显示的效率和稳定性.
主要方法:
- 生成表达CD19.2的oFV向量 (oFV-Δbel2和oFV-bel2),这些向量可以表达CD19.
- 在实验室中评估CAR T细胞杀死.
- 使用皮下瘤模型进行体内研究,以评估治疗疗效和病毒清除.
- 对病毒基因组稳定性和逃生机制的分析.
主要成果:
- 这两种oFV载体在体外显示相同的CAR T细胞杀死.
- 在体内,CAR T细胞减少了oFV生物发光,表明受感染细胞的清除.
- 高剂量的oFV单疗比组合疗法更有效,这表明CAR T细胞是有害的.
- 逃离的瘤显示oFV与CD19转基因的删除,表明病毒逃离.
结论:
- 瘤泡状病毒作为一种缓慢传播的瘤毒剂,产生抗瘤疗法.
- 通过清除受感染细胞,CAR T细胞疗法可以消除ofV的抗瘤作用.
- 进一步开发具有增强免疫治疗策略的oFV平台可能使慢性瘤溶解组合有效.
相关概念视频
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
01:27Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
01:03Rous Sarcoma Virus (RSV) and Cancer
5.0K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.0K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K